JavaScript seems to be disabled in your browser. For the best experience on our site, be sure to turn on Javascript in your browser.
The content, articles and product information provided on this website are strictly educational and informational. They are intended to be used for in vitro research only. “In vitro” is a Latin phrase, “in glass,” that refers to research that is conducted outside of a living organism. Note, these products are not pharmaceuticals or medicines and have not been approved by the FDA for the diagnosis, treatment or prevention of any illnesses or disorders. These products are legally prohibited from human or animal consumption.
BPC-157 and TB-500 represent two distinct research compounds with complementary receptor pharmacology profiles studied extensively in cell-based assay formats. BPC-157 demonstrates specific VEGFR2 receptor interactions, FAK/paxillin signaling cascade activation, and NO synthase pathway modulation. TB-500, the synthetic analog of thymosin β4, exhibits unique binding characteristics with G-actin and demonstrates distinct integrin receptor pharmacology. Published in vitro research characterizes their individual molecular interactions, binding affinity profiles, and downstream pathway engagement in defined cell model systems under controlled laboratory conditions.
BPC-157 functions through VEGFR2 receptor pharmacology, engaging FAK/paxillin signaling networks and NO synthase pathway activation. Competitive radioligand binding assays demonstrate specific binding characteristics with nanomolar affinity ranges in endothelial cell models. The compound exhibits non-competitive inhibition kinetics in certain receptor assays while displaying positive allosteric modulation in others.
Flow cytometry analysis reveals concentration-dependent VEGFR2 phosphorylation patterns in HUVEC cell cultures. Immunofluorescence microscopy studies document FAK autophosphorylation at Tyr397 and subsequent paxillin recruitment to focal adhesion complexes. Western blot analysis confirms downstream Akt pathway phosphorylation following BPC-157 exposure in multiple cell line models.
TB-500 demonstrates high-affinity binding to monomeric G-actin through well-characterized protein-protein interactions. Surface plasmon resonance experiments reveal binding kinetics with KD values in the low micromolar range. The compound exhibits specific integrin receptor engagement, particularly αvβ3 and α5β1 subtypes, documented through competitive binding displacement assays.
Cell-based actin polymerization assays show TB-500's capacity to modulate F-actin assembly dynamics. Time-lapse fluorescence microscopy reveals enhanced lamellipodia formation and membrane ruffling in fibroblast cultures. Biochemical fractionation studies demonstrate increased soluble actin pools following TB-500 treatment in various cell model systems.
The combination of BPC-157 and TB-500 activates distinct yet interconnected cellular signaling cascades. BPC-157-mediated VEGFR2 activation triggers PI3K/Akt pathway engagement, while TB-500's actin-binding properties facilitate cytoskeletal reorganization events. These pathways converge at multiple regulatory nodes, including Rho family GTPase modulation and MAPK cascade integration.
Phosphoproteomic analysis reveals enhanced signal amplification when both compounds are present in cell culture systems. Kinetic studies demonstrate temporal coordination between VEGFR2 phosphorylation events and actin dynamics modifications. Co-immunoprecipitation experiments identify novel protein complex formations involving both pathway components.
Michaelis-Menten kinetic analysis of BPC-157 demonstrates competitive inhibition patterns with endogenous VEGF ligands. Hill coefficient calculations suggest positive cooperativity in receptor binding under specific conditions. Scatchard plot analysis confirms multiple binding site populations with varying affinity characteristics.
TB-500 exhibits concentration-dependent actin binding with sigmoidal dose-response curves. Isothermal titration calorimetry reveals thermodynamic parameters governing actin-TB-500 complex formation. Fluorescence polarization assays quantify binding stoichiometry and cooperative binding mechanisms in purified protein systems.
Primary endothelial cell cultures provide optimal models for studying BPC-157's VEGFR2-mediated effects. Tube formation assays on Matrigel substrates demonstrate enhanced network complexity following compound treatment. Real-time PCR analysis reveals upregulation of specific transcription factors associated with endothelial activation pathways.
TB-500's effects are particularly evident in fibroblast cell line systems where actin dynamics play crucial roles. Scratch wound assays document enhanced directional migration patterns. Live-cell imaging reveals coordinated lamellipodia extension and focal adhesion turnover dynamics.
BPC-157 and TB-500 demonstrate complementary receptor pharmacology profiles with distinct binding characteristics and signaling pathway activation patterns. BPC-157's VEGFR2 receptor interactions and FAK/paxillin signaling engagement combine synergistically with TB-500's actin-binding properties and integrin receptor modulation. Cell-based assays reveal enhanced pathway integration when both compounds are present, suggesting potential for combined research applications. The characterized binding affinities, enzyme kinetics, and downstream signaling cascade modifications provide valuable frameworks for continued in vitro research investigations in controlled laboratory environments.
All content is intended for in vitro laboratory research purposes only. Not for human or animal consumption. Not intended to diagnose, treat, cure, or prevent any condition.
Forgot password?
Country: United States (US-only registration)
All products on this site are for Research, Development use only. Products are Not for Human consumption of any kind. The statements made within this website have not been evaluated by the US Food and Drug Administration. The statements and the products of this company are not intended to diagnose, treat, cure or prevent any disease.
ElementSarms is a chemical supplier. ElementSarms is not a compounding pharmacy or chemical compounding facility as defined under 503A of the Federal Food, Drug, and Cosmetic act. ElementSarms is not an outsourcing facility as defined under 503B of the Federal Food, Drug, and Cosmetic act.
